McKESSON CORPORATION (MCK) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | 410.98B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | (m) | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 6.50B USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $410.98B | (m) | $6.50B | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $403.43B | (m) | $6.21B | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $397.96B | (m) | $5.65B | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $387.09B | (m) | $5.26B | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $377.60B | (m) | $4.43B | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $359.05B | (m) | $4.42B | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $344.58B | (m) | $4.05B | $300.00M | (m) | (m) | 13.49× | Reported |
| 2024-09-30 | (m) | $330.19B | (m) | $3.46B | $297.00M | (m) | (m) | 11.67× | Reported |
| 2024-06-30 | (m) | $313.75B | (m) | $3.84B | $280.00M | (m) | (m) | 13.71× | Reported |
| 2024-03-31 | (m) | $308.95B | (m) | $3.91B | $252.00M | (m) | (m) | 15.51× | Reported |
| 2023-12-31 | (m) | $301.51B | (m) | $3.67B | $251.00M | (m) | (m) | 14.63× | Reported |
| 2023-09-30 | (m) | $291.10B | (m) | $4.27B | $256.00M | (m) | (m) | 16.69× | Reported |
| 2023-06-30 | (m) | $284.04B | (m) | $4.45B | $250.00M | (m) | (m) | 17.78× | Reported |
| 2023-03-31 | (m) | $276.71B | (m) | $4.38B | $248.00M | (m) | (m) | 17.67× | Reported |
| 2022-12-31 | (m) | $273.90B | (m) | $4.03B | $212.00M | (m) | (m) | 19.03× | Reported |
| 2022-09-30 | (m) | $272.03B | (m) | $3.09B | $184.00M | (m) | (m) | 16.80× | Reported |
| 2022-06-30 | (m) | $268.45B | (m) | $2.51B | $174.00M | (m) | (m) | 14.40× | Reported |
| 2022-03-31 | (m) | $263.97B | (m) | $2.04B | $178.00M | (m) | (m) | 11.45× | Reported |
| 2021-12-31 | (m) | $257.01B | (m) | $2.42B | $187.00M | (m) | (m) | 12.91× | Reported |
| 2021-09-30 | (m) | $250.99B | (m) | $-5.25B | $201.00M | (m) | (m) | -26.09× | Reported |
| 2021-06-30 | (m) | $245.22B | (m) | $-5.15B | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $238.23B | (m) | $-5.04B | $217.00M | (m) | (m) | -23.23× | Reported |
| 2020-12-31 | (m) | $237.62B | (m) | $-5.18B | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $234.19B | (m) | $2.54B | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $231.00B | (m) | $2.53B | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $96.00M | $231.05B | (m) | $2.49B | $249.00M | 0.04% | (m) | 10.00× | Reported |
| 2019-12-31 | (m) | $224.94B | (m) | $1.05B | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $221.98B | (m) | $1.37B | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $217.44B | (m) | $1.44B | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $71.00M | $214.32B | (m) | $886.00M | (m) | 0.03% | (m) | (m) | (m) |
| 2018-12-31 | (m) | $213.52B | (m) | $511.00M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $210.93B | (m) | $662.00M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $209.91B | (m) | $212.00M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $125.00M | $208.36B | $69.00M | $762.00M | (m) | 0.06% | 0.03% | (m) | (m) |
| 2017-12-31 | (m) | $205.44B | $63.00M | $6.43B | (m) | (m) | 0.03% | (m) | (m) |
| 2017-09-30 | (m) | $201.96B | $93.00M | $6.43B | (m) | (m) | 0.05% | (m) | (m) |
| 2017-06-30 | (m) | $199.85B | (m) | $6.77B | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $341.00M | $198.53B | $115.00M | $7.11B | (m) | 0.17% | 0.06% | (m) | (m) |
| 2016-12-31 | (m) | $196.50B | $119.00M | $3.12B | (m) | (m) | 0.06% | (m) | (m) |
| 2016-09-30 | (m) | $194.27B | $124.00M | $3.21B | (m) | (m) | 0.06% | (m) | (m) |
| 2016-06-30 | (m) | $193.07B | (m) | $3.59B | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $392.00M | $190.88B | $123.00M | $3.54B | (m) | 0.21% | 0.06% | (m) | (m) |
| 2015-12-31 | (m) | $189.13B | $160.00M | $3.50B | (m) | (m) | 0.08% | (m) | (m) |
| 2015-09-30 | (m) | $187.72B | $170.00M | $3.38B | (m) | (m) | 0.09% | (m) | (m) |
| 2015-06-30 | (m) | $183.12B | (m) | $3.22B | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $392.00M | $179.04B | $174.00M | $2.97B | (m) | 0.22% | 0.10% | (m) | (m) |
| 2014-12-31 | (m) | $173.87B | $172.00M | $2.79B | (m) | (m) | 0.10% | (m) | (m) |
| 2014-09-30 | (m) | $161.20B | $169.00M | $2.50B | (m) | (m) | 0.10% | (m) | (m) |
| 2014-06-30 | (m) | $149.43B | (m) | $2.40B | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | $456.00M | $137.61B | $160.00M | $2.37B | (m) | 0.33% | 0.12% | (m) | (m) |
| 2013-12-31 | (m) | $130.37B | $159.00M | $2.45B | (m) | (m) | 0.12% | (m) | (m) |
| 2013-09-30 | (m) | $127.16B | $158.00M | $2.46B | (m) | (m) | 0.12% | (m) | (m) |
| 2013-06-30 | (m) | $123.96B | (m) | $2.39B | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | $480.00M | $122.45B | $167.00M | $2.31B | (m) | 0.39% | 0.14% | (m) | (m) |
| 2012-12-31 | (m) | $123.53B | $164.00M | $2.38B | (m) | (m) | 0.13% | (m) | (m) |
| 2012-09-30 | (m) | $123.19B | $158.00M | $2.39B | (m) | (m) | 0.13% | (m) | (m) |
| 2012-06-30 | (m) | $123.55B | $157.00M | $2.26B | (m) | (m) | 0.13% | (m) | (m) |
| 2012-03-31 | $440.00M | $122.73B | $154.00M | $2.15B | (m) | 0.36% | 0.13% | (m) | (m) |
| 2011-12-31 | (m) | $119.89B | $151.00M | $2.06B | (m) | (m) | 0.13% | (m) | (m) |
| 2011-09-30 | (m) | $117.30B | $149.00M | $1.88B | (m) | (m) | 0.13% | (m) | (m) |
| 2011-06-30 | (m) | $114.61B | $143.00M | $1.82B | (m) | (m) | 0.12% | (m) | (m) |
| 2011-03-31 | $407.00M | $112.08B | $137.00M | $1.82B | (m) | 0.36% | 0.12% | (m) | (m) |
| 2010-12-31 | (m) | $109.87B | $130.00M | $1.77B | (m) | (m) | 0.12% | (m) | (m) |
| 2010-09-30 | (m) | $109.90B | $127.00M | $1.97B | (m) | (m) | 0.12% | (m) | (m) |
| 2010-06-30 | (m) | $109.50B | $123.00M | $2.02B | (m) | (m) | 0.11% | (m) | (m) |
| 2010-03-31 | $376.00M | $108.70B | $114.00M | $2.01B | (m) | 0.35% | 0.10% | (m) | (m) |
| 2009-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-03-31 | $364.00M | $106.63B | $99.00M | $1.20B | (m) | 0.34% | 0.09% | (m) | (m) |
| 2008-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-03-31 | $347.00M | $101.70B | $91.00M | $1.48B | (m) | 0.34% | 0.09% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cencora, Inc. (COR) | United States | $59.130B | 20.57 |
| CARDINAL HEALTH INC (CAH) | United States | $51.753B | 29.38 |
| HERBALIFE LTD. (HLF) | $1.281B | 8.39 | |
| NU SKIN ENTERPRISES, INC. (NUS) | United States | $0.225B | -1.18 |
| Cosmos Health Inc. (COSM) | Greece | $0.038B | -0.60 |
| HWH International Inc. (HWH) | United States | $0.021B | -4.08 |
| DataMeds AI, Inc. (MEDS) | United States | $0.011B |